Comments on: Will Outsourcing Cool Off? A Recent Poll Finds… http://www.pharmalot.com/2008/05/will-outsourcing-cool-off-a-recent-poll-finds/ News, Comment and Conversation Fri, 10 Feb 2012 22:43:55 +0000 http://wordpress.org/?v=2.6.2 By: Chris http://www.pharmalot.com/2008/05/will-outsourcing-cool-off-a-recent-poll-finds/#comment-345441 Chris Tue, 06 May 2008 01:12:12 +0000 http://www.pharmalot.com/?p=13476#comment-345441 At first glance I'd surmise that the smaller companies can't afford to outsource and/or are regionally focused. It seems that they would be the ones looking to save on services but I think other considerations preclude that. Next, the larger ones that can afford to outsource appear to have done so already. This year follows their bumper outsourcing year: early adopters and all that. So the next tier of adopters (if we still can use that term) are outsourcing but as a percentage their activities represent a drop. Just an opinion: don't think it's over by any means, just shifting down the curve. And for what it's worth, Ed's post last week and other insights point to significantly greater use of outside services, especially in clinical trials. Look at the recent FT articles relating to how much work from EU is ending up in China, Russia, India and Argentina. (And if NICE in UK keeps hacking prices there will be more too.) It's not over, it's just different. At first glance I’d surmise that the smaller companies can’t afford to outsource and/or are regionally focused. It seems that they would be the ones looking to save on services but I think other considerations preclude that.

Next, the larger ones that can afford to outsource appear to have done so already. This year follows their bumper outsourcing year: early adopters and all that. So the next tier of adopters (if we still can use that term) are outsourcing but as a percentage their activities represent a drop.

Just an opinion: don’t think it’s over by any means, just shifting down the curve.

And for what it’s worth, Ed’s post last week and other insights point to significantly greater use of outside services, especially in clinical trials. Look at the recent FT articles relating to how much work from EU is ending up in China, Russia, India and Argentina. (And if NICE in UK keeps hacking prices there will be more too.)

It’s not over, it’s just different.

]]>